These findings indicate that SPARC levels are elevated in patients with CD and in colitis‐induced mice, leading to intestinal barrier damage through direct interaction with OTUD4 and subsequent activation of the MYD88/p65/MLCK/MLC2 signaling pathway. Here, SPARC is linked to colitis.